Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Ganciclovir
Based on the results of a single dose administration study of recommended doses of oral
mycophenolate mofetil and intravenous ganciclovir and the known effects of renal impairment on the
pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-
administration of these agents (which compete for mechanisms of renal tubular secretion) will result in
increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics
is anticipated and mycophenolate mofetil dose adjustment is not required. In patients with renal
impairment in whom mycophenolate mofetil and ganciclovir or its prodrugs, e.g. valganciclovir, are
co-administered, the dose recommendations for ganciclovir should be observed and patients should be
monitored carefully.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ganciclovir
Based on the results of a single dose administration study of recommended doses of oral
mycophenolate mofetil and intravenous ganciclovir and the known effects of renal impairment on the
pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-
administration of these agents (which compete for mechanisms of renal tubular secretion) will result in
increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics
is anticipated and mycophenolate mofetil dose adjustment is not required. In patients with renal
impairment in whom mycophenolate mofetil and ganciclovir or its prodrugs, e.g. valganciclovir, are
co-administered, the dose recommendations for ganciclovir should be observed and patients should be
monitored carefully.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ganciclovir
Based on the results of a single dose administration study of recommended doses of oral
mycophenolate mofetil and intravenous ganciclovir and the known effects of renal impairment on the
pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-
administration of these agents (which compete for mechanisms of renal tubular secretion) will result in
increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics
is anticipated and mycophenolate mofetil dose adjustment is not required. In patients with renal
impairment in whom mycophenolate mofetil and ganciclovir or its prodrugs, e.g. valganciclovir, are
co-administered, the dose recommendations for ganciclovir should be observed and patients should be
monitored carefully.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ganciclovir
Based on the results of a single dose administration study of recommended doses of oral
mycophenolate mofetil and intravenous ganciclovir and the known effects of renal impairment on the
pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-
administration of these agents (which compete for mechanisms of renal tubular secretion) will result in
increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics
is anticipated and mycophenolate mofetil dose adjustment is not required. In patients with renal
impairment in whom mycophenolate mofetil and ganciclovir or its prodrugs, e.g. valganciclovir, are
co-administered, the dose recommendations for ganciclovir should be observed and patients should be
monitored carefully.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 9aa3f032344af173028047af9819cd74a9ef5d92948d189a77af991b5c2334fd · Zeichen 5353–6175 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.